President and CEO
Wayne has held numerous, senior positions in multi-national companies and has lived in seven countries during the past 25 years. Through his career, he has been responsible for building and managing multibillion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO.
From 2005 to 2013 he held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular medicine.
Between 1999 and 2005, Wayne served at Roche Pharmaceuticals where he was Head of Pharmaceuticals in Roche’s South Korean operation, following his role as Head of Commercial Operations for Roche China based in Shanghai.
From April 2015 until November 2016, Wayne served as a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California.
He holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology.
He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.
David St Denis
Chief Operating Officer
David is an accomplished senior healthcare leader with a systematic and metrics-driven approach spanning 20 years of proven business results at the regional and global levels within the life sciences and pharmaceutical sectors.
Most recently at Merck in Germany, he headed commercial operations for Europe and Canada. He has an extensive track record in charge of complex cross-functional and multi-cultural teams that have achieved impressive business objectives in both mature markets (US, Europe, Japan) and developing markets (Brazil, Russia, India, China and Mexico).
His core competencies include operations management, strategy development, marketing and sales, new product introduction and launch excellence, market access and pricing.
David has a Bachelor of Science from the University of Connecticut, a Masters of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College – Franklin W. Olin Graduate School of Business.
In March 2019 Ms Martha Engel commenced as the group’s General Counsel. As a registered patent attorney in the US, Ms Engel has over a decade of legal experience providing advice to companies ranging from medical device manufacturers to craft breweries on all aspects of intellectual property law. She also has a well-rounded legal background on corporate, regulatory, and business transactions. Ms Engel was named an Up & Coming Attorney of the Year by Minnesota Lawyer in 2018. Prior to joining Admedus, she was a partner at the US law firm of Winthrop & Weinstine.
After college, Ms Engel worked in corporate quality at Harley-Davidson Motor Company’s headquarters, applying process improvement methodologies to all areas of the business. She also was an engineer at Falk Corporation, where she designed gearing & power transmission systems for mining, manufacturing, and transportation applications.
Ms Engel has a Bachelor of Science in Mechanical Engineering from Marquette University and a Juris Doctor from William Mitchell College of Law. She is licensed to practice law in Minnesota and the United States Patent & Trademark Office.
Chief Financial Officer
Mr McDonnell worked for KPMG for over 24 years’ including 10 years as a partner. He has a broad range of industry experience and corporate governance acumen, having delivered audit, accounting, and advisory services to a broad range of sectors.
During his time at KPMG he worked predominantly in Australia covering financial services, transport, industrial markets, health, childcare and energy. He has experience in restructures, acquisitions divestments, privatisations and other significant financial transactions.
He was notably involved in Queensland Government restructures and privatisations; Linc Energy’s re-listing on the Singapore Exchange, acquisitions such as Virgin Australia’s purchase of Skywest. He was also Director of the State Library of Queensland and was the Chair of the Audit and Risk Management Committee for eight years.
Dr Kiran Bhirangi
Chief Medical Officer
Dr Bhirangi is a qualified vascular surgeon and brings substantial global leadership in medical affairs and clinical research in the field of cardiology.
He has a deep and thorough knowledge of complex international regulatory and reimbursement environments, having worked across the entire spectrum of device development, launch and evaluation. Previously, he was VP Clinical Development and Medical Affairs for Cardiome AG, Head of Medical Affairs for Europe Shire Human Genetic Therapies and Medical Director at OrthoBiotech, a Johnson and Johnson company.
He has a Bachelor of Medicine, Bachelor of Surgery and Master of Surgery from Bombay University and Fellowship of the Royal College of Surgeons in Ireland. He is widely published and has conducted extensive industrysponsored research.